Skip to content

Cannabis and Seniors

Cannabis and Seniors

As more and more research comes out regarding the medical benefits of cannabis, it’s important to keep up with new research as it becomes available.  Here at Arfinn Med, we constantly review new studies and look at our own deidentified efficacy data to try to find any additional insights we can relay to our registered users. With that in mind, we took a closer look at research coming out of the University of Illinois and the University of Iowa regarding the medicinal benefit of cannabis on Seniors.

The research found “strong positive association” between the frequency of cannabis use by Seniors and self-reported improvements in pain, health-care utilization, and overall health-related quality of life. The researchers revealed they had “identified a strong positive association between higher frequency of cannabis use and improvement to HRQL and HCU [health-care utilization] scores.”

With many clinics seeing an increase in the amount of Seniors turning to medical cannabis, we wanted to identify some additional trends through querying our database of deidentified data for patient demographics 60 and above.

Similar to what this report indicated, we found that Seniors self-reported an average 3.7 resolution of symptoms which translates on our scale to just below a ‘significant resolution’ of symptoms. In addition to the overall efficacy, we found that chronic pain was the most frequently sited qualifying condition with both THC dominant and balanced ratios of THC and CBD being the most frequently used cannabis profiles.  Lastly, in terms of mode of consumption, tinctures were the preferred route.

If you are interested in learning more about the efficacy of medical cannabis and would like to add our electronic medical record (EMR), practice management, and telehealth platform to your practice, please schedule a quick demo by contacting info@arfinnmed.com or by clicking here!

Stories you may be interested in

Older adults and medical marijuana: Reduced stigma and increased use

As a primary care doctor who has incorporated medical cannabis into his practice, it is notable how many silver-haired patients are coming in to discuss the pros and cons of a trial of medical cannabis. These patients range from people in their 60s with kidney failure who can no longer take certain pain medications but…
Read More →

Military Times: “Our veterans deserve the well-being that medical cannabis can provide.”

The physical and mental trauma that veterans experience as a result of their military service extends far beyond the end of their participation in combat-related roles. To recognize the sacrifices veterans have made to protect our country, state and federal lawmakers must continue to expand access to crucial treatment options and programs that assist veterans…
Read More →

Substance in cannabis ‘could boost pancreatic cancer treatments’

A substance found in cannabis plants might boost treatments for patients with pancreatic cancer, research in mice has suggested. Cannabidiol, or CBD, is not psychoactive, meaning it does not produce feelings of being high in those who take it. It is extracted from hemp plants and is legal in the UK, although a CBD product…
Read More →

Scientists Discover Two New Cannabinoids

The plant Cannabis sativa produces more than 400 chemicals, but only one, THC, gets you high. Or so it seems. A group of Italian researchers announced on December 30th the discovery of two new cannabinoids, chemicals produced by weed like THC and CBD. The first, tetrahydrocannabiphorol (THCP), is allegedly 30 times more potent than THC, they claim.…
Read More →

Medical marijuana users tell their stories to Medical Cannabis Study Commission

Thursday, the Medical Cannabis Study Commission held its third meeting. The Commission has been tasked with presenting a policy recommendation to the legislature on exactly what the best medical marijuana bill should look like. The Commission held a public hearing in which a number of medical marijuana users claimed that the drug has benefitted them.…
Read More →

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More →

Leave a Comment

You must be logged in to post a comment.